Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27947333 | 0.75 | FGFR1 (0.43) | KDM4EKMT2AMEN1MAPTNPC1 | |
| SCHEMBL7409270 | 0.75 | DYRK3 (0.43) | KDM4EKMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL2862 | 0.73 | — | — | |
| SCHEMBL440275 | 0.70 | MAPK13 (0.41) | KDM4ELMNAHSD17B10KMT2AMEN1 | |
| SCHEMBL21001888 | 0.68 | KDM4E (0.37) | NQO2KDM4ELMNAHSD17B10KMT2A | |
| SCHEMBL356787 | 0.67 | MEN1 (0.46) | NQO2KDM4ELMNAHSD17B10KMT2A | |
| SCHEMBL207131 | 0.67 | ALPL (0.41) | KDM4EKMT2APDE3BPDE3A | |
| SCHEMBL207659 | 0.67 | F7 (0.42) | KDM4EHSD17B10KMT2AMEN1MAPT | |
| SCHEMBL5981619 | 0.67 | DYRK1A (0.42) | KDM4ELMNAKMT2AMEN1MAPT | |
| SCHEMBL10973210 | 0.67 | PRKCI (0.47) | KDM4EHSD17B10KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040966-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-22 | — | — | US | claimed |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-29 | — | — | US | claimed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | claimed |
| EP-2855453-B1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | claimed |
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-18 | — | — | US | claimed |
| EP-0061094-B1 | ELECTROPHOTOGRAPHIC RECORDING MATERIAL | BASF Aktiengesellschaft (DE) | 1985-10-02 | — | — | EP | claimed |
| EP-0061091-B1 | ELECTROPHOTOGRAPHIC RECORDING MATERIAL | BASF Aktiengesellschaft (DE) | 1985-08-28 | — | — | EP | claimed |
| US-4481272-A | ISOINDOLE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1984-11-06 | — | — | US | claimed |
| US-4389475-A | ISOINDOLE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1983-06-21 | — | — | US | claimed |
| EP-0061094-A1 | Electrophotographic recording material | BASF Aktiengesellschaft (DE) | 1982-09-29 | — | — | EP | claimed |
| US-11040966-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-22 | — | — | US | disclosed |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-29 | — | — | US | disclosed |
| US-10329287-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-25 | — | — | US | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| US-9732075-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-15 | — | — | US | disclosed |
| WO-1999026933-A1 | SUBSTITUTED AMIDINOARYL DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | AXYS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0061094-B1 | ELECTROPHOTOGRAPHIC RECORDING MATERIAL | BASF Aktiengesellschaft (DE) | 1985-10-02 | — | — | EP | disclosed |
| US-4481272-A | ISOINDOLE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1984-11-06 | — | — | US | disclosed |
| US-4389475-A | ISOINDOLE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1983-06-21 | — | — | US | disclosed |
| EP-0061094-A1 | Electrophotographic recording material | BASF Aktiengesellschaft (DE) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | NQO2 917/4885KDM4E 2288/4885LMNA 2615/4885 |
| US-10329287-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | NQO2 905/4885KDM4E 2320/4885LMNA 2613/4885 |
| US-11040966-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | NQO2 905/4885KDM4E 2320/4885LMNA 2613/4885 |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | NQO2 905/4885KDM4E 2320/4885LMNA 2613/4885 |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | NQO2 905/4885KDM4E 2320/4885LMNA 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.